Chronic Myelogenous Leukemia for Primary Care Physicians
| Autor: | Ehab Atallah, Rami Y. Haddad, Sara Torgerson |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Leukocytosis Biopsy Fine-Needle Dasatinib Fusion Proteins bcr-abl Primary care Philadelphia chromosome Piperazines Translocation Genetic Myelogenous Bone Marrow Pregnancy Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine Humans Medicine Philadelphia Chromosome Protein Kinase Inhibitors Primary Health Care Platelet Count business.industry General Medicine medicine.disease Thiazoles Leukemia Pyrimidines Imatinib mesylate Benzamides Disease Progression Imatinib Mesylate Female business Pregnancy Complications Neoplastic Chronic myelogenous leukemia medicine.drug |
| Zdroj: | Disease-a-Month. 58:168-176 |
| ISSN: | 0011-5029 |
| DOI: | 10.1016/j.disamonth.2012.01.007 |
| Popis: | hronic myelogenous leukemia (CML) represents approximately 15% to 0% of the leukemias in adults, with an annual incidence of 1 to 2 cases er 100,000 (approximately 5000 new cases in the USA per year). The edian age at presentation is 45 to 55 years, although all age groups, ncluding children, are affected. The male-to-female ratio is 1.4:1. he prevalence of CML is steadily increasing in the Western world ecause of the dramatic effect of tyrosine kinase inhibitors (TKI) on urvival. It is estimated that there will be 250,000 CML patients living ith CML in the USA by the year 2040. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect